Weiss B

Center for Psychedelic and Consciousness Research, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.

2 preprints · 22 papers · ORCID

PreprintKetamine

Neurite Complexity and Plasticity Markers Track Synaptic Vesicle Density in the Living Human Brain: A Multimodal PET-MRI-EEG Study

Agnorelli C, Peill J, Kurtin DL +25

Europe PMC2026
ArticlePsychedelics

Psychedelics Trials and Outcomes- A Closer Look.

Nayak SM, Weiss B, Yaden DB

Europe PMC2026
ArticlePsilocybin

Correction to: Preliminary Evidence of Sleep Improvements Following Psilocybin Administration, and their Involvement in Antidepressant Therapeutic Action.

Reid MJ, Kettner H, Blanken TF +2

Europe PMC2026
ArticleKetamine

Detecting neuroplastic effects induced by ketamine in healthy human subjects: A multimodal approach.

Agnorelli C, Peill J, Sawicka G +18

Europe PMC2026
ArticleDMT

A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial.

Erritzoe D, Barba T, Benway T +15

Europe PMC2026
ArticlePsychedelics

Neutral attitude toward the utilization of psychedelic therapy for depression in the United Kingdom population.

Jarvis LO, Jack AH, Galbraith N +2

Europe PMC2025
PreprintKetamine

Detecting neuroplastic effects induced by ketamine in healthy human subjects: a multimodal approach

Agnorelli C, Peill J, Sawicka G +16

Europe PMC2025
ArticlePsilocybin

A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research.

Yaden DB, Graziosi M, Owen AM +39

Europe PMC2025
ArticlePsilocybin

An investigation of acute physiological and psychological moderators of psychedelic-induced personality change among healthy volunteers.

Godfrey K, Weiss B, Zhang X +5

Europe PMC2025
ArticlePsilocybin

Preliminary Evidence of Sleep Improvements Following Psilocybin Administration, and their Involvement in Antidepressant Therapeutic Action.

Reid MJ, Kettner H, Blanken TF +2

Europe PMC2024
ArticlePsilocybin

Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial.

Erritzoe D, Barba T, Greenway KT +9

Europe PMC2024
ArticlePsychedelics

Psychiatric risks for worsened mental health after psychedelic use.

Marrocu A, Kettner H, Weiss B +3

Europe PMC2024
ArticlePsilocybin

Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression.

Szigeti B, Weiss B, Rosas FE +3

Europe PMC2024
ArticleMDMA

Preliminary evidence for the importance of therapeutic alliance in MDMA-assisted psychotherapy for posttraumatic stress disorder.

Zeifman RJ, Kettner H, Ross S +4

Europe PMC2024
ArticlePsilocybin

Psilocybin and Other Classic Psychedelics in Depression.

Nutt DJ, Peill JM, Weiss B +3

Europe PMC2024
ArticleAyahuasca

Ayahuasca in the treatment of posttraumatic stress disorder: Mixed-methods case series evaluation in military combat veterans.

Weiss B, Dinh-Williams LL, Beller N +3

Europe PMC2024
ArticleAyahuasca

Ayahuasca: A review of historical, pharmacological, and therapeutic aspects.

Ruffell SGD, Crosland-Wood M, Palmer R +13

Europe PMC2023
ArticleAyahuasca

Prevalence and therapeutic impact of adverse life event reexperiencing under ceremonial ayahuasca.

Weiss B, Wingert A, Erritzoe D +1

Europe PMC2023
ArticlePsilocybin

Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression.

Weiss B, Ginige I, Shannon L +8

Europe PMC2024
ArticleAyahuasca

Examining the Therapeutic Effect of Ceremonial Ayahuasca on Narcissistic Personality and Antagonistic Externalizing in Adults.

Weiss B, Sleep C, Miller JD +1

Europe PMC2023
ArticlePsilocybin

Canalization and plasticity in psychopathology.

Carhart-Harris RL, Chandaria S, Erritzoe DE +11

Europe PMC2023
ArticleAyahuasca

Prospective examination of the therapeutic role of psychological flexibility and cognitive reappraisal in the ceremonial use of ayahuasca.

Agin-Liebes G, Zeifman R, Luoma JB +3

Europe PMC2022
ArticlePsychedelics

Examining Psychedelic-Induced Changes in Social Functioning and Connectedness in a Naturalistic Online Sample Using the Five-Factor Model of Personality.

Weiss B, Nygart V, Pommerencke LM +2

Europe PMC2021
ArticleAyahuasca

Examining changes in personality following shamanic ceremonial use of ayahuasca.

Weiss B, Miller JD, Carter NT +1

Europe PMC2021